Congress locks in drug discounts for safety-net clinics at checkout
H.R. 7391 — Community Health Center Drug Pricing Protection Act · Filed by Jack Bergman (R-MI) · 56 cosponsors · Introduced Feb 5, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the 340B drug pricing program to require that Federally-qualified health centers (FQHCs) pay the statutory ceiling price for covered drugs at the point of purchase, not through later rebates or reconciliation. It bars manufacturers from charging FQHCs more upfront and then clawing back the difference later, ensuring these safety-net clinics get the discount immediately when they buy.
Why we flagged it
The bill's operative mechanism is a timing and pricing transparency requirement—it mandates that the discount be applied at point of purchase rather than through post-hoc reconciliation. This is a structural fix to the 340B program's mechanics, not a price-setting intervention, and it benefits public health providers' operational cash flow.
What the text implies
- Manufacturers may respond by tightening supply agreements, imposing volume minimums, or requiring pre-purchase commitments from FQHCs to manage their own cash flow under upfront pricing.
- The rule of construction in subsection (b) explicitly blocks 'later reconciliation by rebate, reimbursement, or other payment'—this forecloses a common industry practice and may trigger manufacturer litigation over contract interpretation.
The full analysis lists 4 implications of this text.
Who stands to gain
Federally-qualified health centers (FQHCs); Safety-net clinics and community health providers